Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach

Table 3 Differences in baseline characteristics between chemotherapy, chemoradiation therapy and chemotherapy plus chemoradiation therapy groups

Variables	Group A, n = 65	Group B, n = 62	Group C, n = 208	P value
Female, n (%)	23 (35.4)	27 (43.5)	93 (44.7)	0.410
Age ≥ 70, n (%)	24 (36.9)	26 (41.9)	48 (23.1)	0.005
ECOG, n (%)				0.009
0	47 (72.3)	47 (75.8)	181 (87.0)
1	18 (27.7)	15 (24.2)	27 (13.0)
Histology, n (%)				0.160
WD/MD	52 (80.0)	55 (88.7)	185 (88.9)
PD/UD	10 (15.4)	7 (11.3)	15 (7.2)
Unknown	3 (4.6)	0 (0.0)	8 (3.8)
Charlson's index ≥ 6, n (%)	17 (26.2)	20 (32.3)	41 (19.7)	0.101
Safety margin ≤ 0.1 cm, n (%)	26 (40.0)	32 (51.6)	68 (32.7)	0.024
CA19-9 ≥ 100 U/mL, n (%)	26 (40.0)	36 (58.1)	113 (54.6)	0.074
Lymphovascular invasion, n (%)	27 (41.5)	34 (54.8)	87 (42.0)	0.435
Perineural invasion, n (%)	54 (83.1)	56 (90.3)	170 (81.7)	0.275
Surgery type, n (%)				0.388
Pancreaticoduodenectomy	42 (64.6)	38 (61.3)	142 (68.3)
Distal pancreatectomy	19 (29.2)	24 (38.7)	59 (28.4)
Subtotal pancreatectomy	1 (1.5)	0 (0.0)	3 (1.4)
Total pancreatectomy	3 (4.6)	0 (0.0)	4 (1.9)
AJCC stage, n (%)				0.080
IA/IB	19 (29.2)	28 (45.2)	89 (42.8)
IIA/IIB	37 (56.9)	21 (33.9)	82 (39.4)
III	9 (13.8)	13 (21.0)	37 (17.8)
Duration to initial adjuvant treatment in d	46.8 ± 15.3	43.9 ± 18.4	48.8 ± 18.0	0.223
Treatment duration	39.8 ± 9.9	143.2 ± 47.5	194.8 ± 48.2	< 0.001

Group A: Chemoradiation therapy; Group B: Chemotherapy, Group C: Chemotherapy plus chemoradiation therapy. AJCC: American Joint Committee on Cancer; CA 19-9: Carbohydrate antigen 19-9; ECOG: Eastern Cooperative Oncology Group; MD: Moderately differentiated; PD: Poorly differentiated; UD: Undifferentiated; WD: Well differentiated.